Landscape Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Landscape Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.04M	Buy	3,935 +3,503	+811%	+$2.68M	0.19%	164
2025 Q4	$333K	Sell	432 -624	-59%	-$424K	0.02%	531
2025 Q3	$594K	Buy	+1,056	New	+$597K	0.04%	434
2025 Q2	–	Sell	-1,628	Closed	-$1.03M	–	801
2025 Q1	$1.03M	Buy	+1,628	New	+$1.12M	0.09%	290
2019 Q4	–	Sell	-1,259	Closed	-$349K	–	798
2019 Q3	$349K	Sell	1,259 -699	-36%	-$207K	0.03%	494
2019 Q2	$613K	Hold	1,958	–	–	0.05%	370
2019 Q1	$804K	Sell	1,958 -103	-5%	-$42.4K	0.08%	307
2018 Q4	$770K	Buy	2,061 +138	+7%	+$50.5K	0.06%	330
2018 Q3	$777K	Buy	+1,923	New	+$732K	0.06%	318
2018 Q1	–	Sell	-2,143	Closed	-$806K	–	634
2017 Q4	$806K	Buy	+2,143	New	+$868K	0.07%	286
2014 Q2	–	Sell	-800	Closed	-$240K	–	350
2014 Q1	$240K	Buy	+800	New	+$246K	0.32%	79

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Landscape Capital Management's REGN Position: Q1 2026 in Review

Landscape Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 811% in Q1 2026, buying an estimated $2.68M and bringing the position to 3,935 shares worth $3.04M. The position accounts for 0.19% of the portfolio, ranked #164.

Landscape Capital Management first reported a position in REGN in Q1 2014 and has held it in 11 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Landscape Capital Management held 3,935 shares of Regeneron Pharmaceuticals worth $3.04M as of Q1 2026.
Landscape Capital Management bought 3,503 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.68M.
Regeneron Pharmaceuticals made up 0.19% of Landscape Capital Management's portfolio in Q1 2026, its #164 holding.
Landscape Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Landscape Capital Management's 13F filing for Q1 2026, filed 12 May 2026.